Clarivate (CLVT) Projected to Post Quarterly Earnings on Tuesday

Clarivate (NYSE:CLVT) will likely be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $604.7930 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 9:00 AM ET.

Clarivate Price Performance

CLVT stock opened at $1.81 on Tuesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.87 and a current ratio of 0.87. The business has a 50-day simple moving average of $2.99 and a two-hundred day simple moving average of $3.55. The company has a market capitalization of $1.19 billion, a P/E ratio of -3.17 and a beta of 1.51. Clarivate has a 52-week low of $1.74 and a 52-week high of $5.16.

Insiders Place Their Bets

In other Clarivate news, insider Bar Veinstein sold 309,902 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $3.74, for a total value of $1,159,033.48. Following the completion of the sale, the insider directly owned 848,811 shares of the company’s stock, valued at $3,174,553.14. This trade represents a 26.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 23.18% of the company’s stock.

Institutional Investors Weigh In On Clarivate

Several large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of Clarivate by 537.7% in the third quarter. Russell Investments Group Ltd. now owns 38,406 shares of the company’s stock worth $147,000 after acquiring an additional 32,383 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Clarivate by 3.9% in the third quarter. Envestnet Asset Management Inc. now owns 77,275 shares of the company’s stock valued at $296,000 after acquiring an additional 2,884 shares during the period. Worldquant Millennium Advisors LLC purchased a new position in Clarivate during the second quarter valued at approximately $225,000. Quantinno Capital Management LP grew its stake in Clarivate by 88.3% during the second quarter. Quantinno Capital Management LP now owns 68,156 shares of the company’s stock valued at $293,000 after acquiring an additional 31,970 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in Clarivate by 128.6% during the 2nd quarter. Sei Investments Co. now owns 43,447 shares of the company’s stock worth $187,000 after acquiring an additional 24,442 shares during the period. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on CLVT shares. Wall Street Zen raised Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. The Goldman Sachs Group downgraded shares of Clarivate from a “buy” rating to a “neutral” rating and lowered their target price for the company from $4.20 to $3.60 in a report on Thursday, January 8th. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price objective (down from $5.00) on shares of Clarivate in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $4.28.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.